Inovio Pharmaceuticals, Inc. (INO Stock) Price Prediction: Rebounds on new COVID-19 vaccine American deal
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:INO gained 1.72% on Wednesday as new optimism over COVID-19 vaccines arose.
- News of US President Trump ordering another batch of Pfizer doses hit the media.
- Other coronavirus vaccine firms like Moderna agreed to new deals with different countries.
NASDAQ:INO finally saw an end to its recent skid as it rebounded by 1.72% during Wednesday’s trading session and pushed back over the $10 price barrier. The biotech stock has been beaten down over the past month as heavy delays to its clinical trials caused Inovio to fall well behind in the race for a COVID-19 vaccine. Inovio still holds a mean 12-month price target of $13.71 so the recent sell-off by investors could be a little overblown considering the company is still in the process of testing its vaccine candidate.
Speaking of vaccine candidates, many of the pharmaceutical companies involved in Operation Warp Speed rallied on Wednesday as new deals to secure doses of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) were agreed by the United States and Canada respectively. These deals triggered optimism in investors as the demand for vaccines for the novel coronavirus are still here, despite fear over a new strain of the virus in the United Kingdom. The public is also warming up to receive the covid injections as public figures such as President-elect Joe Biden have already done it on camera.
Inovio Pharmaceuticals, Inc. Stock Price
It is difficult to say whether Inovio is a good investment at this point in time. With every passing day, the firm falls further behind the other companies and there are still no real efficacy results for their vaccine candidate INO-4800. While the world definitely needs more lifesaver shots in the near future, it is difficult to imagine governments reaching for Inovio over the existing, more established vaccines.
- NASDAQ:INO gained 1.72% on Wednesday as new optimism over COVID-19 vaccines arose.
- News of US President Trump ordering another batch of Pfizer doses hit the media.
- Other coronavirus vaccine firms like Moderna agreed to new deals with different countries.
NASDAQ:INO finally saw an end to its recent skid as it rebounded by 1.72% during Wednesday’s trading session and pushed back over the $10 price barrier. The biotech stock has been beaten down over the past month as heavy delays to its clinical trials caused Inovio to fall well behind in the race for a COVID-19 vaccine. Inovio still holds a mean 12-month price target of $13.71 so the recent sell-off by investors could be a little overblown considering the company is still in the process of testing its vaccine candidate.
Speaking of vaccine candidates, many of the pharmaceutical companies involved in Operation Warp Speed rallied on Wednesday as new deals to secure doses of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) were agreed by the United States and Canada respectively. These deals triggered optimism in investors as the demand for vaccines for the novel coronavirus are still here, despite fear over a new strain of the virus in the United Kingdom. The public is also warming up to receive the covid injections as public figures such as President-elect Joe Biden have already done it on camera.
Inovio Pharmaceuticals, Inc. Stock Price
It is difficult to say whether Inovio is a good investment at this point in time. With every passing day, the firm falls further behind the other companies and there are still no real efficacy results for their vaccine candidate INO-4800. While the world definitely needs more lifesaver shots in the near future, it is difficult to imagine governments reaching for Inovio over the existing, more established vaccines.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.